NanoGuardian's NanoEncryption technology is the only on-dose, multi-layered, brand protection solution that enables pharmaceutical manufacturers to authenticate and trace every single dose, from plant-to-patient. NanoGuardian's Closed-Loop Protection Program combines the on-dose authentication and tracing benefits of NanoEncryption technology with a proactive supply chain auditing program to identify counterfeit or illegally-diverted pharmaceuticals entering the global supply chain as early as possible.
“While pharmaceutical manufacturers have done a great job securing the packaging of medications, illegally diverted and counterfeited drugs are often repackaged before they reach the patient, necessitating the need for on-dose security,” said Dean Hart, chief commercial officer of NanoGuardian. “We are extremely pleased a leading, global pharmaceutical company has made the decision to protect its key products at the dose level with NanoGuardian's NanoEncryption technology. Through their leadership, we are moving closer to ensuring the integrity of the global pharmaceutical supply chain and protecting the patients that rely on these medications every day for their health and well-being.”
“With this move, one company has stepped forward to increase patient safety with an additional, heightened level of security. I am certain that this step will lead to a new standard which other pharmaceutical companies will surely follow,” said Dr. John Glover, a pharmaceutical security expert and co-founder of the Pharmaceutical Security Institute. “This decision recognizes that package security alone will not provide the level of patient safety necessary in today's high-tech, international trading environment. On-dose security is a critical component in ensuring product authenticity. This decision will lead to a new standard of product security.”
Dr. John Glover is a pharmaceutical security expert with a distinguished career spanning more than 35 years with the FBI, Bristol-Myers Squibb Company, the Pharmaceutical Security Institute and the U.S. State Department. Today, Dr. Glover serves as president of John Glover Consulting, Inc., which provides consulting services to a very select number of prominent corporate and non-governmental entities. Dr. Glover is also the chair of NanoGuardian's Security Advisory Board.
NanoGuardian fights both counterfeiting and illegal diversion with a single technology that can be used to protect capsules, tablets, vial caps, and single-use syringes providing a layered security of overt, covert, and forensic features. The overt and covert security features allow dose-level authentication at any point in the supply chain, while the forensic and nano-scale NanoCodes provide comprehensive tracing information on each and every dose. NanoGuardian's technology provides a strong benefit over other on-dose technologies given that NanoGuardian's security features are implemented with no additional material or chemicals being added to the medication.
NanoGuardian's Closed-Loop Protection market monitoring program works hand-in-hand with NanoEncryption technology to provide manufacturers an early warning system in the detection of counterfeit and diverted product. Through random audits at retail pharmacies, NanoGuardian's Closed-Loop Protection program can proactively detect counterfeit and diverted product, providing manufacturers with early detection of problems and mitigating risk to brands, companies and patients.
As evidence of the rapidly growing problem of counterfeit pharmaceuticals, a recent report from the U.S. Customs and Border Protection and the U.S. Immigration and Customs Enforcement noted that the domestic value of counterfeit pharmaceutical seizures in fiscal year 2011 rose by more than $11 million, an increase of almost 200 percent. The implications for victims of counterfeit drugs are extremely serious, often resulting in unexpected side effects, severe allergic reactions and even death.